Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Jan 25

PMID 39861681

Authors

Yawen Wang

Lei Yang

Qing Xu

Taiyu Liu

Hongliang He

Lisha Liu

Lifang Yin

Affiliations

Soon will be listed here.

Abstract

Liver fibrosis, a hallmark of chronic liver diseases, is characterized by excessive extracellular matrix (ECM) deposition and scar tissue formation. Current antifibrotic nanomedicines face significant limitations, including poor penetration into fibrotic tissue, rapid clearance, and suboptimal therapeutic efficacy. The dense fibrotic ECM acts as a major physiological barrier, necessitating the development of a targeted delivery strategy to achieve effective therapeutic outcomes. We designed a liposomal delivery system functionalized with the GBI-10 aptamer and encapsulating obeticholic acid (OCA lips@Apt) to enhance selective delivery to fibrotic liver tissue while minimizing systemic toxicity. Both in vitro and in vivo studies demonstrated that the aptamer-modified OCA liposomes effectively treated hepatic fibrosis through dual mechanisms: modulation of abnormal bile acid metabolism and attenuation of inflammation. The targeted delivery system leveraged the overexpression of Tenascin-C (TnC), a key ECM component in fibrotic tissues, for precise localization and enhanced endocytosis via the exposed cationic liposome surface. The OCA lips@Apt nanodrug demonstrated superior therapeutic efficacy with minimal off-target effects, offering a promising strategy to overcome critical barriers in liver fibrosis treatment. By precisely targeting the fibrotic ECM and modulating key pathological pathways, this TnC-guided liposomal delivery system provides a significant advancement in antifibrotic nanomedicine.

References

Dewidar B, Meyer C, Dooley S, Meindl-Beinker A . TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. Cells. 2019; 8(11). PMC: 6912224. DOI: 10.3390/cells8111419. View

Han C, Rho H, Kim A, Kim T, Jang K, Won Jun D . FXR Inhibits Endoplasmic Reticulum Stress-Induced NLRP3 Inflammasome in Hepatocytes and Ameliorates Liver Injury. Cell Rep. 2018; 24(11):2985-2999. DOI: 10.1016/j.celrep.2018.07.068. View

Attia Y, Tawfiq R, Ali A, Elmazar M . The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway. Sci Rep. 2017; 7(1):12502. PMC: 5624958. DOI: 10.1038/s41598-017-12629-4. View

Fan Y, Ding W, Zhang C, Fu L, Xu D, Chen X . Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3. Int Immunopharmacol. 2019; 77:105911. DOI: 10.1016/j.intimp.2019.105911. View

Wang Y, Chen W, Wang M, Yu D, Forman B, Huang W . Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008; 48(5):1632-43. PMC: 3056574. DOI: 10.1002/hep.22519. View

Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X . Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis. Biomed Pharmacother. 2023; 161:114472. DOI: 10.1016/j.biopha.2023.114472. View

Borkham-Kamphorst E, Weiskirchen R . The PDGF system and its antagonists in liver fibrosis. Cytokine Growth Factor Rev. 2015; 28:53-61. DOI: 10.1016/j.cytogfr.2015.10.002. View

Hammerich L, Tacke F . Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023; 20(10):633-646. DOI: 10.1038/s41575-023-00807-x. View

Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y . Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Front Cell Dev Biol. 2021; 9:730176. PMC: 8490799. DOI: 10.3389/fcell.2021.730176. View

10.

Rinella M, Dufour J, Anstee Q, Goodman Z, Younossi Z, Harrison S . Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2021; 76(3):536-548. DOI: 10.1016/j.jhep.2021.10.029. View

11.

Vivero-Escoto J, Vadarevu H, Juneja R, Schrum L, Benbow J . Nanoparticle mediated silencing of tenascin C in hepatic stellate cells: effect on inflammatory gene expression and cell migration. J Mater Chem B. 2019; 7(46):7396-7405. DOI: 10.1039/c9tb01845j. View

12.

Pei Q, Yi Q, Tang L . Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities. Int J Mol Sci. 2023; 24(11). PMC: 10253436. DOI: 10.3390/ijms24119671. View

13.

Zhuge A, Li S, Yuan Y, Han S, Xia J, Wang Q . Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice. Redox Biol. 2022; 59:102582. PMC: 9830314. DOI: 10.1016/j.redox.2022.102582. View

14.

He X, Chen X, Liu L, Zhang Y, Lu Y, Zhang Y . Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. Adv Sci (Weinh). 2018; 5(5):1701070. PMC: 5979633. DOI: 10.1002/advs.201701070. View

15.

Kim J, Kim Y . The evidence-based multifaceted roles of hepatic stellate cells in liver diseases: A concise review. Life Sci. 2024; 344:122547. DOI: 10.1016/j.lfs.2024.122547. View

16.

Armstrong L, Guo G . Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis. Curr Pharmacol Rep. 2017; 3(2):92-100. PMC: 5624538. DOI: 10.1007/s40495-017-0085-2. View

17.

Li K, Deng J, Jin H, Yang X, Fan X, Li L . Chemical modification improves the stability of the DNA aptamer GBI-10 and its affinity towards tenascin-C. Org Biomol Chem. 2017; 15(5):1174-1182. DOI: 10.1039/c6ob02577c. View

18.

Zhao X, Yee Kwan J, Yip K, Liu P, Liu F . Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2019; 19(1):57-75. DOI: 10.1038/s41573-019-0040-5. View

19.

Tian S, Chen S, Pan C, Li Y . FXR: structures, biology, and drug development for NASH and fibrosis diseases. Acta Pharmacol Sin. 2022; 43(5):1120-1132. PMC: 9061771. DOI: 10.1038/s41401-021-00849-4. View

20.

Arab J, Karpen S, Dawson P, Arrese M, Trauner M . Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 2016; 65(1):350-362. PMC: 5191969. DOI: 10.1002/hep.28709. View